GlobalData on MSN

Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer

Pelthos Therapeutics has secured the rights to market non-fluorinated quinolone antimicrobial, Xepi (ozenoxacin) cream, 1% in ...

Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing

Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™Xepi is a novel FDA-approved ...

Antibody-Mediated Rejection Market Set to Expand Significantly During the Forecast Period (2025-2034) Amid Advances in Diagnostics and Targeted Therapies | DelveIn…

DelveInsight's Antibody-mediated Rejection Market Insights report includes a comprehensive understanding of current treatment ...

Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Results from an interim analysis in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients remain on track for 4Q 2025Expect to ...

DelveInsight Business Research, LLP: Antibody-Mediated Rejection Market Set to Expand Significantly During the Forecast Period (2025-2034) Amid Advances in Diagnostics and ...

The antibody-mediated rejection market is expanding as the number of organ transplants rises and awareness of AMR's impact on graft survival grows. Advances in diagnostic assays ...
Zacks Small Cap Research on MSN

LGND: Target Up On Improved Growth Outlook

LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported outstanding results for its third ...